Terms: = Skin cancer AND PRF1, P14222, PFP, P1, MGC65093, HPLH2, FLH2, ENSG00000180644, 5551 AND Treatment
37 results:
1. Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM.
Placke JM; Kimmig M; Griewank K; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Welzel J; Engel DR; Kreft S; Sucker A; Lodde G; Krefting F; Stoffels I; Klode J; Roesch A; Zimmer L; Livingstone E; Hadaschik E; Becker JC; Weichenthal M; Tasdogan A; Schadendorf D; Ugurel S
EBioMedicine; 2023 Oct; 96():104774. PubMed ID: 37660535
[TBL] [Abstract] [Full Text] [Related]
2. Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS).
Canaud G; Lopez Gutierrez JC; Irvine AD; Vabres P; Hansford JR; Ankrah N; Branle F; Papadimitriou A; Ridolfi A; O'Connell P; Turner S; Adams DM
Genet Med; 2023 Dec; 25(12):100969. PubMed ID: 37634128
[TBL] [Abstract] [Full Text] [Related]
3. Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study.
Meric-Bernstam F; Calvo E; Lee KS; Moreno V; Park YH; Rha SY; Chalasani P; Zhong W; Zhou L; Pirie-Shepherd S; Leung ACF; Curigliano G
Mol Cancer Ther; 2023 Oct; 22(10):1191-1203. PubMed ID: 37420274
[TBL] [Abstract] [Full Text] [Related]
4. Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma.
Coleman S; Xie M; Tarhini AA; Tan AC
Mol Carcinog; 2023 Jan; 62(1):77-89. PubMed ID: 35781709
[TBL] [Abstract] [Full Text] [Related]
5. Comparative Clinical Efficacy of 'Concurrent Chemoradiotherapy (CCRT) and Anlotinib' Than CCRT in Patients with Locally Advanced ESCC.
Wang G; Beeraka NM; Xiao W; Zhang Y; Xue N; Chen G; Liu J; Liu Y
Technol Cancer Res Treat; 2022; 21():15330338221080939. PubMed ID: 35235470
[No Abstract] [Full Text] [Related]
6. Parotidectomy and neck dissection in locally advanced and relapsed cutaneous squamous cell carcinoma of the head and neck region.
Melo GM; Guilherme LH; Palumbo MDN; Rosano M; Neves MCD; Callegari FM; Abrahao M; Cervantes O
Braz J Otorhinolaryngol; 2022; 88 Suppl 4(Suppl 4):S152-S162. PubMed ID: 35042657
[TBL] [Abstract] [Full Text] [Related]
7. Indurated Plaques on the Legs: Think Lymphoma.
Watts-Santos A; Cuellar-Barboza A; Ramos-Cavazos CJ; Villarreal-Martinez A; Ocampo-Candiani J; Herz-Ruelas ME
Acta Dermatovenerol Croat; 2021 Jul; 29(2):114-115. PubMed ID: 34477080
[TBL] [Abstract] [Full Text] [Related]
8. Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review.
de Lorenzi C; André R; Vuilleumier A; Kaya G; Abosaleh M
Ann Dermatol Venereol; 2020 Mar; 147(3):221-227. PubMed ID: 31982173
[TBL] [Abstract] [Full Text] [Related]
9. Enhancing doxorubicin anticancer activity with a novel polymeric platform photoreleasing nitric oxide.
Sodano F; Cavanagh RJ; Pearce AK; Lazzarato L; Rolando B; Fraix A; Abelha TF; Vasey CE; Alexander C; Taresco V; Sortino S
Biomater Sci; 2020 Mar; 8(5):1329-1344. PubMed ID: 31912808
[TBL] [Abstract] [Full Text] [Related]
10. skin sparing mastectomy and robotic latissimus dorsi-flap reconstruction through a single incision.
Houvenaeghel G; Bannier M; Rua S; Barrou J; Heinemann M; Lambaudie E; Cohen M
World J Surg Oncol; 2019 Nov; 17(1):176. PubMed ID: 31677640
[TBL] [Abstract] [Full Text] [Related]
11. DNA Damage Response After Ionizing Radiation Exposure in skin Keratinocytes Derived from Human-Induced Pluripotent Stem Cells.
Miyake T; Shimada M; Matsumoto Y; Okino A
Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):193-205. PubMed ID: 31085283
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.
Lee EB; Yamanaka H; Liu Y; Tsai WC; Chen C; Kwok K; Yoo HJ; Llamado LJ; Wang L; Luo Y; Sugiyama N; Tanaka Y
Int J Rheum Dis; 2019 Jun; 22(6):1094-1106. PubMed ID: 30900375
[TBL] [Abstract] [Full Text] [Related]
13. A Bowman-Birk type chymotrypsin inhibitor peptide from the amphibian, Hylarana erythraea.
Zhang L; Chen X; Wu Y; Zhou M; Ma C; Xi X; Chen T; Walker B; Shaw C; Wang L
Sci Rep; 2018 Apr; 8(1):5851. PubMed ID: 29643444
[TBL] [Abstract] [Full Text] [Related]
14. Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, With Spontaneous Regression After Biopsy.
Marrero-Alemán G; Montenegro-Dámaso T; Peñate Y
Am J Dermatopathol; 2017 Oct; 39(10):785-787. PubMed ID: 28926365
[TBL] [Abstract] [Full Text] [Related]
15. Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme.
Curtis JR; Lee EB; Martin G; Mariette X; Terry KK; Chen Y; Geier J; Andrews J; Kaur M; Fan H; Nduaka CI
Clin Exp Rheumatol; 2017; 35(4):614-622. PubMed ID: 28240592
[TBL] [Abstract] [Full Text] [Related]
16. The nitrobenzoxadiazole derivative MC3181 blocks melanoma invasion and metastasis.
De Luca A; Carpanese D; Rapanotti MC; Viguria TM; Forgione MA; Rotili D; Fulci C; Iorio E; Quintieri L; Chimenti S; Bianchi L; Rosato A; Caccuri AM
Oncotarget; 2017 Feb; 8(9):15520-15538. PubMed ID: 28107182
[TBL] [Abstract] [Full Text] [Related]
17. Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.
Curtis JR; Zhang R; Krishnaswami S; Anisfeld A; Chen Y; Strengholt S; Chen C; Geier J
Clin Rheumatol; 2017 Mar; 36(3):683-688. PubMed ID: 27470086
[TBL] [Abstract] [Full Text] [Related]
18. Etoposide-Bevacizumab a new strategy against human melanoma cells expressing stem-like traits.
Calvani M; Bianchini F; Taddei ML; Becatti M; Giannoni E; Chiarugi P; Calorini L
Oncotarget; 2016 Aug; 7(32):51138-51149. PubMed ID: 27303923
[TBL] [Abstract] [Full Text] [Related]
19. Mutant B-Raf(V600E) Promotes Melanoma Paracellular Transmigration by Inducing Thrombin-mediated Endothelial Junction Breakdown.
Zhang P; Feng S; Liu G; Wang H; Zhu H; Ren Q; Bai H; Fu C; Dong C
J Biol Chem; 2016 Jan; 291(5):2087-106. PubMed ID: 26504080
[TBL] [Abstract] [Full Text] [Related]
20. Five-year experience with infliximab: Follow up of the product familiarisation program.
Nguyen R; Braue A; Baker C; Foley P
Australas J Dermatol; 2016 Nov; 57(4):300-306. PubMed ID: 26374405
[TBL] [Abstract] [Full Text] [Related]
[Next]
